Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder

Epidemiology and Psychiatric Sciences

Volumn 26, Issue 1, 2017, Pages 22-36

  Kessler, R C ^a   Van Loo, H M ^b   Wardenaar, K J ^b   Bossarte, R M ^c   Brenner, L A ^d   Ebert, D D ^a,e   De Jonge, P ^b   Nierenberg, A A ^f   Rosellini, A J ^a   Sampson, N A ^a   Schoevers, R A ^b   Wilcox, M A ^g   Zaslavsky, A M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Depression; epidemiology; evidence based psychiatry; research design and methods; treatment allocation

Indexed keywords

AMFEBUTAMONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AREA UNDER THE CURVE; CLINICAL DECISION MAKING; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; MACHINE LEARNING; MAJOR DEPRESSION; MEDICAL RECORD; MENTAL HEALTH; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PSYCHOANALYSIS; PSYCHOTHERAPY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SELF REPORT; TREATMENT RESPONSE;

EID: 84955582646     PISSN: 20457960     EISSN: 20457979     Source Type: Journal    
DOI: 10.1017/S2045796016000020     Document Type: Review

References (136)

1. Agid O, Lerer B (2003). Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 6, 41-49.
2. Altshuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP, Ross RW (2001). Treatment of depression in women: a summary of the expert consensus guidelines. Journal of Psychiatric Practice 7, 185-208.
3. American Psychiatric Association (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. American Psychiatric Association: Arlington, VA.
4. Andreasen NC, Grove WM (1982). The classification of depression: traditional versus mathematical approaches. The American Journal of Psychiatry 139, 45-52.
5. Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY, Pollock BG, Stack J, Miller MD, Reynolds CF (2007). Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. The British Journal of Psychiatry: The Journal of Mental Science 190, 344-349.
6. Andreescu C, Chang CC, Mulsant BH, Ganguli M (2008a). Twelve-year depressive symptom trajectories and their predictors in a community sample of older adults. International Psychogeriatrics/IPA 20, 221-236.
7. Andreescu C, Mulsant BH, Houck PR, Whyte EM, Mazumdar S, Dombrovski AY, Pollock BG, Reynolds CF III (2008b). Empirically derived decision trees for the treatment of late-life depression. The American Journal of Psychiatry 165, 855-862.
8. Anglemyer A, Horvath HT, Bero L (2014). Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. The Cochrane Database of Systematic Reviews 4, MR000034.
9. Angst J, Gamma A, Rossler W, Ajdacic V, Klein DN (2011). Childhood adversity and chronicity of mood disorders. European Archives of Psychiatry and Clinical Neuroscience 261, 21-27.
10. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A (2012). Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Research and Treatment 133, 1-10.
11. Bagby RM, Quilty LC, Segal ZV, McBride CC, Kennedy SH, Costa PT (2008). Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie 53, 361-370.
12. Barber JP, Muenz LR (1996). The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program. Journal of Consulting and Clinical Psychology 64, 951-958.
13. Baumeister H, Gordon P (2012). Meta-review of depressive subtyping models. Journal of Affective Disorders 139, 126-140.
14. Bellino S, Paradiso E, Bogetto F (2008). Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 22, 671-692.
15. Bernecker SL, Constantino MJ, Pazzaglia AM, Ravitz P, McBride C (2014). Patient interpersonal and cognitive changes and their relation to outcome in interpersonal psychotherapy for depression. Journal of Clinical Psychology 70, 518-527.
16. Bradvik L, Mattisson C, Bogren M, Nettelbladt P (2008). Long-term suicide risk of depression in the Lundby cohort 1947-1997 - severity and gender. Acta Psychiatrica Scandinavica 117, 185-191.
17. Breitenstein B, Scheuer S, Holsboer F (2014). Are there meaningful biomarkers of treatment response for depression? Drug Discovery Today 19, 539-561.
18. Burke JF, Hayward RA, Nelson JP, Kent DM (2014). Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circulation: Cardiovascular Quality and Outcomes 7, 163-169.
19. Carter JD, Luty SE, McKenzie JM, Mulder RT, Frampton CM, Joyce PR (2011). Patient predictors of response to cognitive behaviour therapy and interpersonal psychotherapy in a randomised clinical trial for depression. Journal of Affective Disorders 128, 252-261.
20. Chang YJ, Chen LJ, Chung KP, Lai MS (2012). Risk groups defined by Recursive Partitioning Analysis of patients with colorectal adenocarcinoma treated with colorectal resection. BMC Medical Research Methodology 12, 2.
21. Chao ST, Koyfman SA, Woody N, Angelov L, Soeder SL, Reddy CA, Rybicki LA, Djemil T, Suh JH (2012). Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. International Journal of Radiation Oncology, Biology, Physics 82, 1738-1743.
22. Cohen A, Houck PR, Szanto K, Dew MA, Gilman SE, Reynolds CF (2006). Social inequalities in response to antidepressant treatment in older adults. Archives of General Psychiatry 63, 50-56.
23. Cohen A, Gilman SE, Houck PR, Szanto K, Reynolds CF (2009). Socioeconomic status and anxiety as predictors of antidepressant treatment response and suicidal ideation in older adults. Social Psychiatry and Psychiatric Epidemiology 44, 272-277.
24. Constantino MJ, Adams ML, Pazzaglia AM, Bernecker SL, Ravitz P, McBride C (2013). Baseline patient characteristics as predictors of remission in interpersonal psychotherapy for depression. Psychotherapy Research: Journal of the Society for Psychotherapy Research 23, 190-200.
25. Cooper C, Jones L, Dunn E, Forty L, Haque S, Oyebode F, Craddock N, Jones I (2007). Clinical presentation of postnatal and non-postnatal depressive episodes. Psychological Medicine 37, 1273-1280.
26. Cooper PJ, Murray L (1995). Course and recurrence of postnatal depression. Evidence for the specificity of the diagnostic concept. The British Journal of Psychiatry: The Journal of Mental Science 166, 191-195.
27. Cronkite RC, Woodhead EL, Finlay A, Timko C, Unger Hu K, Moos RH (2013). Life stressors and resources and the 23-year course of depression. Journal of Affective Disorders 150, 370-377.
28. Cuijpers P, Reynolds CF III, Donker T, Li J, Andersson G, Beekman A (2012). Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depression and Anxiety 29, 855-864.
29. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M, Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE, Zaslavsky AM, Ustun TB, Chatterji S (2004). Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 291, 2581-2590.
30. Denton WH, Carmody TJ, Rush AJ, Thase ME, Trivedi MH, Arnow BA, Klein DN, Keller MB (2010). Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. Psychological Medicine 40, 415-424.
31. DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L (2014). The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PloS ONE 9, e83875.
32. Dew MA, Reynolds CF III, Houck PR, Hall M, Buysse DJ, Frank E, Kupfer DJ (1997). Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. Archives of General Psychiatry 54, 1016-1024.
33. Diaz Munoz I, van der Laan MJ (2011). Super learner based conditional density estimation with application to marginal structural models. The International Journal of Biostatistics 7, Article 38.
34. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK, Atkins DC, Dunner DL, Jacobson NS (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology 74, 658-670.
35. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR (2011). Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 343, d5888.
36. Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TW, Ritchie JC, Rivera VA, Westen D, Craighead WE, Mayberg HS (2012). Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials 13, 106.
37. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P (2008). Population-based study of first onset and chronicity in major depressive disorder. Archives of General Psychiatry 65, 513-520.
38. Echouffo-Tcheugui JB, Kengne AP (2013). Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. Diabetes & Metabolism 39, 389-396.
39. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB (1989). National institute of mental health treatment of depression collaborative research program. General effectiveness of treatments. Archives of General Psychiatry 46, 971-982; discussion 983.
40. Feske U, Frank E, Kupfer DJ, Shear MK, Weaver E (1998). Anxiety as a predictor of response to interpersonal psychotherapy for recurrent major depression: an exploratory investigation. Depression and Anxiety 8, 135-141.
41. Fichter MM, Quadflieg N, Fischer UC, Kohlboeck G (2010). Twenty-five-year course and outcome in anxiety and depression in the Upper Bavarian Longitudinal Community Study. Acta Psychiatrica Scandinavica 122, 75-85.
42. Fink M, Rush AJ, Knapp R, Rasmussen K, Mueller M, Rummans TA, O'Connor K, Husain M, Biggs M, Bailine S, Kellner CH (2007). DSM melancholic features are unreliable predictors of ECT response: a CORE publication. The Journal of ECT 23, 139-146.
43. Fournier JC, DeRubeis RJ, Shelton RC, Gallop R, Amsterdam JD, Hollon SD (2008). Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder. The British Journal of Psychiatry: The Journal of Mental Science 192, 124-129.
44. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R (2009). Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. Journal of Consulting and Clinical Psychology 77, 775-787.
45. Frank E, Cassano GB, Rucci P, Thompson WK, Kraemer HC, Fagiolini A, Maggi L, Kupfer DJ, Shear MK, Houck PR, Calugi S, Grochocinski VJ, Scocco P, Buttenfield J, Forgione RN (2011). Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychological Medicine 41, 151-162.
46. Hastie T, Tibshirani R, Friedman J (2009). The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd edn. Springer: New York.
47. Hayward RA, Kent DM, Vijan S, Hofer TP (2006). Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Medical Research Methodology 6, 18.
48. Hetrick SE, Simmons M, Thompson A, Parker AG (2011). What are specialist mental health clinician attitudes to guideline recommendations for the treatment of depression in young people? The Australian and New Zealand Journal of Psychiatry 45, 993-1001.
49. Hoencamp E, Haffmans PM, Duivenvoorden H, Knegtering H, Dijken WA (1994). Predictors of (non-) response in depressed outpatients treated with a three-phase sequential medication strategy. Journal of Affective Disorders 31, 235-246.
50. Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R (2014). Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 71, 1157-1164.
51. Huibers MJH, Cohen ZD, Lemmens LHJM, Arntz A, Peeters FPML, Cuijpers P, DeRubeis RJ (2015). Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed individuals using the personalized advantage index approach. PLoS ONE 10, e0140771.
52. Ionescu R, Popescu C, Jipescu I (1994). Predictors of outcome in depression. Romanian Journal of Neurology and Psychiatry/ Revue Roumaine de Neurologie et Psychiatrie 32, 153-173.
53. Jain FA, Hunter AM, Brooks JO III, Leuchter AF (2013). Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depression and Anxiety 30, 624-630.
54. James G, Witten D, Hastie T, Tibshirani R (2013). An Introduction to Statistical Learning: with Applications in R. Springer: New York.
55. Jarrett RB, Minhajuddin A, Kangas JL, Friedman ES, Callan JA, Thase ME (2013). Acute phase cognitive therapy for recurrent major depressive disorder: who drops out and how much do patient skills influence response? Behaviour Research and Therapy 51, 221-230.
56. Johnstone JM, Luty SE, Carter JD, Mulder RT, Frampton CM, Joyce PR (2009). Childhood neglect and abuse as predictors of antidepressant response in adult depression. Depression and Anxiety 26, 711-717.
57. Joyce PR, McKenzie JM, Carter JD, Rae AM, Luty SE, Frampton CM, Mulder RT (2007). Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. The British Journal of Psychiatry: The Journal of Mental Science 190, 503-508.
58. Kennedy SH, Andersen HF, Lam RW (2006). Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Journal of Psychiatry & Neuroscience 31, 122-131.
59. Kennedy SH, Downar J, Evans KR, Feilotter H, Lam RW, MacQueen GM, Milev R, Parikh SV, Rotzinger S, Soares C (2012). The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Current Pharmaceutical Design 18, 5976-5989.
60. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA (2010). Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 11, 85.
61. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, 8-19.
62. Kessler RC, Merikangas KR, Berglund P, EatonWW, Koretz DS, Walters EE (2003). Mild disorders should not be eliminated from the DSM-V. Archives of General Psychiatry 60, 1117-1122.
63. Kessler RC, Berglund P, Chiu WT, Demler O, Heeringa S, Hiripi E, Jin R, Pennell BE, Walters EE, Zaslavsky A, Zheng H (2004). The US National Comorbidity Survey Replication (NCS-R): design and field procedures. International Journal of Methods in Psychiatric Research 13, 69-92.
64. Kessler RC, van Loo HM, Wardenaar KJ, Bossarte RM, Brenner LA, Cai T, Ebert DD, Hwang I, Li J, de Jonge P, Nierenberg AA, Petukhova MV, Rosellini AJ, Sampson NA, Schoevers RA, Wilcox MA, Zaslavsky AM (2016). Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports. Molecular Psychiatry.
65. Klein DN, Shankman SA, Rose S (2008). Dysthymic disorder and double depression: prediction of 10-year course trajectories and outcomes. Journal of Psychiatric Research 42, 408-415.
66. Kool S, Schoevers R, de Maat S, Van R, Molenaar P, Vink A, Dekker J (2005). Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. Journal of Affective Disorders 88, 269-278.
67. Kraemer HC (2013). Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Statistics in Medicine 32, 1964-1973.
68. Kuiper S, McLean L, Fritz K, Lampe L, Malhi GS (2013). Getting depression clinical practice guidelines right: time for change? Acta Psychiatrica Scandinavica. Supplementum 24-30.
69. Lamers F, Burstein M, He JP, Avenevoli S, Angst J, Merikangas KR (2012). Structure of major depressive disorder in adolescents and adults in the US general population. The British Journal of Psychiatry: The Journal of Mental Science 201, 143-150.
70. Li C, Lu Y (2010). Evaluating the improvement in diagnostic utility from adding new predictors. Biometrical Journal. Biometrische Zeitschrift 52, 417-435.
71. Lin HW, Chen YH (2014). Adjustment for missing confounders in studies based on observational databases: 2-stage calibration combining propensity scores from primary and validation data. American Journal of Epidemiology 180, 308-317.
72. Liu Y, Nie Z, Zhou J, Farnum M, Narayan VA, Wittenberg G, Ye J (2014). Sparse generalized functional linear model for predicting remission status of depression patients. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 364-375.
73. Lowe B, Schenkel I, Bair MJ, Gobel C (2005). Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients. Journal of Affective Disorders 87, 271-279.
74. Lurie JD, Morgan TS (2013). Pros and cons of pragmatic clinical trials. Journal of Comparative Effectiveness Research 2, 53-58.
75. Luty SE, Carter JD, McKenzie JM, Rae AM, Frampton CM, Mulder RT, Joyce PR (2007). Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. The British Journal of Psychiatry: The Journal of Mental Science 190, 496-502.
76. Madigan CD, Jolly K, Lewis AL, Aveyard P, Daley AJ (2014). A randomised controlled trial of the effectiveness of self-weighing as a weight loss intervention. The International Journal of Behavioral Nutrition and Physical Activity 11, 125.
77. Marquett RM, Thompson LW, Reiser RP, Holland JM, O'Hara RM, Kesler SR, Stepanenko A, Bilbrey A, Rengifo J, Majoros A, Thompson DG (2013). Psychosocial predictors of treatment response to cognitive-behavior therapy for late-life depression: an exploratory study. Aging & Mental Health 17, 830-838.
78. Mattisson C, Bogren M, Horstmann V, Munk-Jorgensen P, Nettelbladt P (2007). The long-term course of depressive disorders in the Lundby Study. Psychological Medicine 37, 883-891.
79. McBride C, Atkinson L, Quilty LC, Bagby RM (2006). Attachment as moderator of treatment outcome in major depression: a randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy. Journal of Consulting and Clinical Psychology 74, 1041-1054.
80. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM (1996). Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Archives of General Psychiatry 53, 232-240.
81. Moos RH, Cronkite RC (1999). Symptom-based predictors of a 10-year chronic course of treated depression. The Journal of Nervous and Mental Disease 187, 360-368.
82. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD (1999). Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. The American Journal of Psychiatry 156, 1000-1006.
83. Nanni V, Uher R, Danese A (2012). Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. The American Journal of Psychiatry 169, 141-151.
84. National Institute for Health and Clinical Excellence (NICE) (2009). Depression: Treatment and Mangement of Depression in Adult. National Institute for Health and Clinical Excellence: London.
85. Nelson JC, Zhang Q, Deberdt W, Marangell LB, Karamustafalioglu O, Lipkovich IA (2012). Predictors of remission with placebo using an integrated study database from patients with major depressive disorder. Current Medical Research and Opinion 28, 325-334.
86. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr., Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB (2003). Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences of the United States of America 100, 14293-14296.
87. Neugebauer R, Schmittdiel JA, van der Laan MJ (2014). Targeted learning in real-world comparative effectiveness research with time-varying interventions. Statistics in Medicine 33, 2480-2520.
88. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. The Journal of Clinical Psychiatry 69, 1287-1292.
89. Perel P, Edwards P, Wentz R, Roberts I (2006). Systematic review of prognostic models in traumatic brain injury. BMC Medical Informatics and Decision Making 6, 38.
90. Perlis RH (2007). Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Current Medical Research and Opinion 23, 467-475.
91. Perlis RH (2013). A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biological Psychiatry 74, 7-14.
92. Perlis RH (2014). Pharmacogenomic testing and personalized treatment of depression. Clinical Chemistry 60, 53-59.
93. Picciotto S, Eisen EA, Chevrier J (2014). 0351 G-estimation: why does it work and what does it offer? Occupational and Environmental Medicine 71 (Suppl. 1), A120-A121.
94. Pizzagalli DA (2011). Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 36, 183-206.
95. Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J (2006). Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. American Journal of Epidemiology 163, 589-599.
96. Prieto-Merino D, Pocock SJ (2012). The science of risk models. European Journal of Preventive Cardiology 19, 7-13.
97. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF (1990). Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Archives of General Psychiatry 47, 935-941.
98. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wager SG, Nunes E, Klein DF (1991). Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Archives of General Psychiatry 48, 319-323.
99. Rabinoff M, Kitchen CM, Cook IA, Leuchter AF (2011). Evaluation of quantitative EEG by classification and regression trees to characterize responders to antidepressant and placebo treatment. The Open Medical Informatics Journal 5, 1-8.
100. Riedel M, Moller HJ, Obermeier M, Adli M, Bauer M, Kronmuller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Seemuller F (2011). Clinical predictors of response and remission in inpatients with depressive syndromes. Journal of Affective Disorders 133, 137-149.
101. Ritchie MD (2005). Bioinformatics approaches for detecting gene-gene and gene-environment interactions in studies of human disease. Neurosurgical Focus 19, E2.
102. Romera I, Delgado-Cohen H, Perez T, Caballero L, Gilaberte I (2008). Factor analysis of the Zung self-rating depression scale in a large sample of patients with major depressive disorder in primary care. BMC Psychiatry 8, 4.
103. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH (2008). Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Archives of General Psychiatry 65, 870-880.
104. Simon GE, Perlis RH (2010). Personalized medicine for depression: can we match patients with treatments? The American Journal of Psychiatry 167, 1445-1455.
105. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP (2012). Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 344, e3318.
106. Smits JA, Minhajuddin A, Thase ME, Jarrett RB (2012). Outcomes of acute phase cognitive therapy in outpatients with anxious versus nonanxious depression. Psychotherapy and Psychosomatics 81, 153-160.
107. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, et al. (1991). Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. The American Journal of Psychiatry 148, 997-1008.
108. Souslova T, Marple TC, Spiekerman AM, Mohammad AA (2013). Personalized medicine in Alzheimer's disease and depression. Contemporary Clinical Trials 36, 616-623.
109. Steyerberg EW, Vedder MM, Leening MJ, Postmus D, D'Agostino RB Sr., Van Calster B, Pencina MJ (2014). Graphical assessment of incremental value of novel markers in prediction models: from statistical to decision analytical perspectives. Biometrical Journal. Biometrische Zeitschrift.
110. Strobl C, Malley J, Tutz G (2009). An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychological Methods 14, 323-348.
111. Suarez D, Haro JM, Novick D, Ochoa S (2008). Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. Journal of Clinical Epidemiology 61, 525-530.
112. Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ (2012). The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. The Journal of Clinical Psychiatry 73, 967-976.
113. Szadoczky E, Rozsa S, Zambori J, Furedi J (2004). Predictors for 2-year outcome of major depressive episode. Journal of Affective Disorders 83, 49-57.
114. Tchetgen Tchetgen E (2014). The control outcome calibration approach for causal inference with unobserved confounding. American Journal of Epidemiology 179
115. Thase ME, Reynolds CF III, Frank E, Simons AD, McGeary J, Fasiczka AL, Garamoni GG, Jennings JR, Kupfer DJ (1994). Do depressed men and women respond similarly to cognitive behavior therapy? The American Journal of Psychiatry 151, 500-505.
116. Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ (1997). Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry 54, 1009-1015.
117. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ (2007). Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology 27, 672-676.
118. Toh S, Manson JE (2013). An analytic framework for aligning observational and randomized trial data: application to postmenopausal hormone therapy and coronary heart disease. Statistics in Biosciences 5.
119. Trivedi MH, Morris DW, Pan JY, Grannemann BD, John Rush A (2005). What moderator characteristics are associated with better prognosis for depression? Neuropsychiatric Disease and Treatment 1, 51-57.
120. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. The American Journal of Psychiatry 163, 28-40.
121. Troxel WM, Kupfer DJ, Reynolds CF III, Frank E, Thase ME, Miewald JM, Buysse DJ (2012). Insomnia and objectively measured sleep disturbances predict treatment outcome in depressed patients treated with psychotherapy or psychotherapy-pharmacotherapy combinations. The Journal of Clinical Psychiatry 73, 478-485.
122. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. The American Journal of Psychiatry 167, 555-564.
123. Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A, Maier W, Henigsberg N, Kalember P, Rietschel M, Placentino A, Mendlewicz J, Aitchison KJ, McGuffin P, Farmer A (2011). Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders 132, 112-120.
124. Upstill-Goddard R, Eccles D, Fliege J, Collins A (2013). Machine learning approaches for the discovery of gene-gene interactions in disease data. Briefings in Bioinformatics 14, 251-260.
125. van der Laan MJ, Gruber S (2010). Collaborative double robust targeted maximum likelihood estimation. The International Journal of Biostatistics 6, Article 17.
126. van der Laan MJ, Rose S (2011). Targeted Learning: Causal Inference for Observational and Experimental Data. Springer: New York.
127. van Loo HM, de Jonge P, Romeijn JW, Kessler RC, Schoevers RA (2012). Data-driven subtypes of major depressive disorder: a systematic review. BMC Medicine 10, 156.
128. van Loo HM, Cai T, Gruber MJ, Li J, de Jonge P, Petukhova M, Rose S, Sampson NA, Schoevers RA, Wardenaar KJ, Wilcox MA, Al-Hamzawi AO, Andrade LH, Bromet EJ, Bunting B, Fayyad J, Florescu SE, Gureje O, Hu C, Huang Y, Levinson D, Medina-Mora ME, Nakane Y, Posada-Villa J, Scott KM, Xavier M, Zarkov Z, Kessler RC (2014). Major depressive disorder subtypes to predict long-term course. Depression and Anxiety 31, 765-777.
129. Van Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, Delaney B, Smeeth L (2012). Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ 344.
130. Vrieze E, Demyttenaere K, Bruffaerts R, Hermans D, Pizzagalli DA, Sienaert P, Hompes T, de Boer P, Schmidt M, Claes S (2014). Dimensions in major depressive disorder and their relevance for treatment outcome. Journal of Affective Disorders 155, 35-41.
131. Vuorilehto MS, Melartin TK, Isometsa ET (2009). Course and outcome of depressive disorders in primary care: a prospective 18-month study. Psychological Medicine 39, 1697-1707.
132. Wallace ML, Frank E, Kraemer HC (2013). A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 70, 1241-1247.
133. Wardenaar KJ, van Loo HM, Cai T, Fava M, Gruber MJ, Li J, de Jonge P, Nierenberg AA, Petukhova MV, Rose S, Sampson NA, Schoevers RA, Wilcox MA, Alonso J, Bromet EJ, Bunting B, Florescu SE, Fukao A, Gureje O, Hu C, Huang YQ, Karam AN, Levinson D, Medina Mora ME, Posada-Villa J, Scott KM, Taib NI, Viana MC, Xavier M, Zarkov Z, Kessler RC (2014). The effects of co-morbidity in defining major depression subtypes associated with long-term course and severity. Psychological Medicine 44, 3289-3302.
134. Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gordon E (2011). International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 12, 4.
135. Willke RJ, Zheng Z, Subedi P, Althin R, Mullins CD (2012). From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Medical Research Methodology 12, 185.
136. Zhang H, Singer BH (2010). Recursive Partitioning and Applications. Springer: New York.